{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:03:40Z","timestamp":1762862620605,"version":"3.44.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jmmc-online.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Molecular and Cellular Cardiology"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.yjmcc.2011.08.005","type":"journal-article","created":{"date-parts":[[2011,8,14]],"date-time":"2011-08-14T17:30:43Z","timestamp":1313343043000},"page":"435-437","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Where are the new drugs to treat heart failure? Introduction to the special issue on \u201cKey signaling molecules in hypertrophy and heart failure\u201d"],"prefix":"10.1016","volume":"51","author":[{"given":"Paul C.","family":"Simpson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.yjmcc.2011.08.005_bb0005","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.yjmcc.2011.03.016","article-title":"Novel targets for the treatment of heart failure: perspectives from a heart failure clinician and trialist","volume":"51","author":"Massie","year":"2011","journal-title":"J Mol Cell Cardiol."},{"issue":"4","key":"10.1016\/j.yjmcc.2011.08.005_bb0010","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.yjmcc.2010.09.026","article-title":"Current NHLBI perspectives on translational heart failure research","volume":"51","author":"Lathrop","year":"2011","journal-title":"J Mol Cell Cardiol."},{"issue":"4","key":"10.1016\/j.yjmcc.2011.08.005_bb0015","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.yjmcc.2011.08.004","article-title":"Heart failure drug discovery: scarred or ready for remodeling?","volume":"51","author":"Plump","year":"2011","journal-title":"J Mol Cell Cardiol."},{"issue":"4","key":"10.1016\/j.yjmcc.2011.08.005_bb0020","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.yjmcc.2011.04.008","article-title":"Preclinical studies of human disease: time to take methodological quality seriously","volume":"51","author":"van der Worp","year":"2011","journal-title":"J Mol Cell Cardiol."},{"issue":"4","key":"10.1016\/j.yjmcc.2011.08.005_bb0025","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.yjmcc.2011.08.002","article-title":"Myocardial salvage in acute myocardial infarction-challenge in clinical translation","volume":"51","author":"Mochly-Rosen","year":"2011","journal-title":"J Mol Cell Cardiol."},{"issue":"4","key":"10.1016\/j.yjmcc.2011.08.005_bb0030","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.yjmcc.2011.05.006","article-title":"Cardiac myosin activation part 1: From concept to clinic","volume":"51","author":"Malik","year":"2011","journal-title":"J Mol Cell Cardiol."},{"issue":"4","key":"10.1016\/j.yjmcc.2011.08.005_bb0035","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.yjmcc.2011.05.015","article-title":"Pharmacologic and genetic strategies to enhance cell therapy for cardiac regeneration","volume":"51","author":"Kanashiro-Takeuchi","year":"2011","journal-title":"J Mol Cell Cardiol."},{"issue":"4","key":"10.1016\/j.yjmcc.2011.08.005_bb0040","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.yjmcc.2010.12.012","article-title":"Translational potential of thyroid hormone and its analogs","volume":"51","author":"Arsanjani","year":"2011","journal-title":"J Mol Cell Cardiol."},{"issue":"4","key":"10.1016\/j.yjmcc.2011.08.005_bb0045","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.yjmcc.2011.06.016","article-title":"Neuregulin-1beta for the treatment of systolic heart failure","volume":"51","author":"Sawyer","year":"2011","journal-title":"J Mol Cell Cardiol."},{"issue":"4","key":"10.1016\/j.yjmcc.2011.08.005_bb0050","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.yjmcc.2010.10.021","article-title":"The p38 mitogen-activated protein kinase pathway\u2014a potential target for intervention in infarction, hypertrophy, and heart failure","volume":"51","author":"Marber","year":"2011","journal-title":"J Mol Cell Cardiol."},{"issue":"4","key":"10.1016\/j.yjmcc.2011.08.005_bb0055","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.yjmcc.2010.10.004","article-title":"Protein kinase Calpha as a heart failure therapeutic target","volume":"51","author":"Liu","year":"2011","journal-title":"J Mol Cell Cardiol."},{"issue":"4","key":"10.1016\/j.yjmcc.2011.08.005_bb0060","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.yjmcc.2010.11.014","article-title":"Alpha-1-adrenergic receptors: targets for agonist drugs to treat heart failure","volume":"51","author":"Jensen","year":"2011","journal-title":"J Mol Cell Cardiol."},{"issue":"2","key":"10.1016\/j.yjmcc.2011.08.005_bb0065","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1161\/01.RES.0000137171.97172.d7","article-title":"Myocardial protection at a crossroads: the need for translation into clinical therapy","volume":"95","author":"Bolli","year":"2004","journal-title":"Circ Res"},{"key":"10.1016\/j.yjmcc.2011.08.005_bb0070","unstructured":"Begley S., Carmichael M. Desperately seeking cures: medical research isn't making progress rapidly enough; here's why-and how to push things forward. Newsweek. 2010; May 24 & 31(http:\/\/www.thedailybeast.com\/newsweek\/2010\/05\/15\/desperately-seeking-cures.html): 38\u201342."},{"year":"2008","series-title":"Pfizer to drop development of drugs for hyperlipidemia, atherosclerosis, and heart failure","author":"Wood","key":"10.1016\/j.yjmcc.2011.08.005_bb0075"},{"key":"10.1016\/j.yjmcc.2011.08.005_bb0080","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1161\/RES.0b013e31822cc630","article-title":"Announcing increased word limits and two new additions to our article portfolio. Perspectives and Translational Success Stories","volume":"109","author":"Bolli","year":"2011","journal-title":"Circ Res"},{"issue":"90","key":"10.1016\/j.yjmcc.2011.08.005_bb0085","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002747","article-title":"Reengineering translational science: the time is right","volume":"3","author":"Collins","year":"2011","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.yjmcc.2011.08.005_bb0090","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1161\/CIRCHEARTFAILURE.109.893222","article-title":"Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward","volume":"3","author":"Felker","year":"2010","journal-title":"Circ Heart Fail"},{"issue":"3","key":"10.1016\/j.yjmcc.2011.08.005_bb0095","doi-asserted-by":"crossref","first-page":"e1000245","DOI":"10.1371\/journal.pmed.1000245","article-title":"Can animal models of disease reliably inform human studies?","volume":"7","author":"van der Worp","year":"2010","journal-title":"PLoS Med"},{"issue":"3","key":"10.1016\/j.yjmcc.2011.08.005_bb0100","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.111.022889","article-title":"Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+\u2212ATPase in patients with advanced heart failure","volume":"124","author":"Jessup","year":"2011","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.yjmcc.2011.08.005_bb0105","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1172\/JCI59681","article-title":"You know what we need?","volume":"121","author":"Neill","year":"2011","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.yjmcc.2011.08.005_bb0110","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.yjmcc.2010.10.033","article-title":"Transforming growth factor (TGF)-beta signaling in cardiac remodeling","volume":"51","author":"Dobaczewski","year":"2011","journal-title":"J Mol Cell Cardiol."},{"issue":"4","key":"10.1016\/j.yjmcc.2011.08.005_bb0115","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.yjmcc.2010.10.008","article-title":"Functions for the cardiomyokine, MANF, in cardioprotection, hypertrophy and heart failure","volume":"51","author":"Glembotski","year":"2011","journal-title":"J Mol Cell Cardiol."},{"issue":"4","key":"10.1016\/j.yjmcc.2011.08.005_bb0120","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.yjmcc.2010.09.019","article-title":"beta(2) AR agonists in treatment of chronic heart failure: long path to translation","volume":"51","author":"Talan","year":"2011","journal-title":"J Mol Cell Cardiol."},{"issue":"4","key":"10.1016\/j.yjmcc.2011.08.005_bb0125","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.yjmcc.2010.11.005","article-title":"beta-Arrestin: a signaling molecule and potential therapeutic target for heart failure","volume":"51","author":"Noor","year":"2011","journal-title":"J Mol Cell Cardiol."},{"issue":"4","key":"10.1016\/j.yjmcc.2011.08.005_bb0130","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.yjmcc.2011.01.012","article-title":"CaMKII in myocardial hypertrophy and heart failure","volume":"51","author":"Anderson","year":"2011","journal-title":"J Mol Cell Cardiol."},{"issue":"4","key":"10.1016\/j.yjmcc.2011.08.005_bb0135","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.yjmcc.2010.12.003","article-title":"Targeting the ACE2-Ang-(1\u20137) pathway in cardiac fibroblasts to treat cardiac remodeling and heart failure","volume":"51","author":"Iwata","year":"2011","journal-title":"J Mol Cell Cardiol."},{"issue":"4","key":"10.1016\/j.yjmcc.2011.08.005_bb0140","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.yjmcc.2010.11.020","article-title":"Targeting GSK-3 family members in the heart: a very sharp double-edged sword","volume":"51","author":"Cheng","year":"2011","journal-title":"J Mol Cell Cardiol."},{"issue":"4","key":"10.1016\/j.yjmcc.2011.08.005_bb0145","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.yjmcc.2010.12.004","article-title":"Targeting AMPK for cardiac protection: opportunities and challenges","volume":"51","author":"Kim","year":"2011","journal-title":"J Mol Cell Cardiol."},{"issue":"4","key":"10.1016\/j.yjmcc.2011.08.005_bb0150","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.yjmcc.2011.01.008","article-title":"Emerging roles of SIRT1 deacetylase in regulating cardiomyocyte survival and hypertrophy","volume":"51","author":"Sundaresan","year":"2011","journal-title":"J Mol Cell Cardiol."},{"issue":"4","key":"10.1016\/j.yjmcc.2011.08.005_bb0155","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.yjmcc.2010.10.020","article-title":"betaIIPKC and epsilonPKC isozymes as potential pharmacological targets in cardiac hypertrophy and heart failure","volume":"51","author":"Ferreira","year":"2011","journal-title":"J Mol Cell Cardiol."},{"issue":"4","key":"10.1016\/j.yjmcc.2011.08.005_bb0160","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.yjmcc.2011.03.009","article-title":"Targeting endothelial and myocardial dysfunction with tetrahydrobiopterin","volume":"51","author":"Moens","year":"2011","journal-title":"J Mol Cell Cardiol."},{"issue":"4","key":"10.1016\/j.yjmcc.2011.08.005_bb0165","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.yjmcc.2011.05.017","article-title":"Bi-modal dose-dependent cardiac response to tetrahydrobiopterin in pressure-overload induced hypertrophy and heart failure","volume":"51","author":"Moens","year":"2011","journal-title":"J Mol Cell Cardiol."},{"issue":"4","key":"10.1016\/j.yjmcc.2011.08.005_bb0170","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.yjmcc.2011.01.004","article-title":"Pim-1 kinase inhibits pathological injury by promoting cardioprotective signaling","volume":"51","author":"Fischer","year":"2011","journal-title":"J Mol Cell Cardiol."},{"issue":"4","key":"10.1016\/j.yjmcc.2011.08.005_bb0175","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.yjmcc.2010.11.009","article-title":"Isoform-selective HDAC inhibitors: closing in on translational medicine for the heart","volume":"51","author":"McKinsey","year":"2011","journal-title":"J Mol Cell Cardiol."},{"issue":"4","key":"10.1016\/j.yjmcc.2011.08.005_bb0180","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.yjmcc.2011.01.006","article-title":"Taking the heart failure battle inside the cell: small molecule targeting of Gbetagamma subunits","volume":"51","author":"Kamal","year":"2011","journal-title":"J Mol Cell Cardiol."},{"issue":"4","key":"10.1016\/j.yjmcc.2011.08.005_bb0185","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.yjmcc.2010.09.020","article-title":"Application of recombinant thioredoxin1 for treatment of heart disease","volume":"51","author":"Matsushima","year":"2011","journal-title":"J Mol Cell Cardiol."},{"issue":"4","key":"10.1016\/j.yjmcc.2011.08.005_bb0190","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.yjmcc.2011.06.010","article-title":"Autophagy as a therapeutic target in cardiovascular disease","volume":"51","author":"Nemchenko","year":"2011","journal-title":"J Mol Cell Cardiol."},{"issue":"4","key":"10.1016\/j.yjmcc.2011.08.005_bb0195","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.yjmcc.2010.09.011","article-title":"Nix nought nothing: fairy tale or real deal","volume":"51","author":"Dorn","year":"2011","journal-title":"J Mol Cell Cardiol."},{"issue":"4","key":"10.1016\/j.yjmcc.2011.08.005_bb0200","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.yjmcc.2010.09.013","article-title":"Small heat shock protein 20 (HspB6) in cardiac hypertrophy and failure","volume":"51","author":"Fan","year":"2011","journal-title":"J Mol Cell Cardiol."},{"issue":"4","key":"10.1016\/j.yjmcc.2011.08.005_bb0205","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.yjmcc.2010.11.003","article-title":"Therapeutic targeting of innate immunity in the failing heart","volume":"51","author":"Topkara","year":"2011","journal-title":"J Mol Cell Cardiol."},{"issue":"4","key":"10.1016\/j.yjmcc.2011.08.005_bb0210","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.yjmcc.2010.09.021","article-title":"The PGC-1 cascade as a therapeutic target for heart failure","volume":"51","author":"Schilling","year":"2011","journal-title":"J Mol Cell Cardiol."}],"container-title":["Journal of Molecular and Cellular Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022282811003233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022282811003233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T20:19:38Z","timestamp":1758313178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022282811003233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0022282811003233"],"URL":"https:\/\/doi.org\/10.1016\/j.yjmcc.2011.08.005","relation":{},"ISSN":["0022-2828"],"issn-type":[{"type":"print","value":"0022-2828"}],"subject":[],"published":{"date-parts":[[2011,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Where are the new drugs to treat heart failure? Introduction to the special issue on \u201cKey signaling molecules in hypertrophy and heart failure\u201d","name":"articletitle","label":"Article Title"},{"value":"Journal of Molecular and Cellular Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yjmcc.2011.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}